

HLS Therapeutics Inc.

## **HLS Therapeutics to Host 2017 Fourth Quarter and Year End Results Conference Call**

TORONTO, March 19, 2018 /CNW/ - HLS Therapeutics Inc. (TSXV: HLS) today announced that it will release its fourth quarter 2017 financial results by press release on Thursday, March 29, 2018, prior to market open. The Company will subsequently hold a conference call that same day, Thursday, March 29, at 8:30 am Eastern Time hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Tim Hendrickson, VP Finance and Administration. A question and answer session will follow the corporate update.

### **Conference Call Details**

DATE:	Thursday, March 29, 2018
TIME:	8:30 am ET
DIAL-IN NUMBER:	(888) 231-8191 or (647) 427-7450
TAPED REPLAY:	(855) 859-2056 or (416) 849-0833
REFERENCE NUMBER:	2483038

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at [www.hlstherapeutics.com](http://www.hlstherapeutics.com). Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast. An archived webcast will be available for one year.

### **About HLS**

HLS (TSXV: HLS) is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established, branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

*Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

SOURCE HLS Therapeutics Inc.

For further information: Ross Marshall, Investor Relations, LodeRock Advisors at (416) 526-1563, or [ross.marshall@loderockadvisors.com](mailto:ross.marshall@loderockadvisors.com); Gilbert Godin, President and Chief Operating Officer of HLS at (484) 232-3400, ext. 101, or [g.godin@hlstherapeutics.com](mailto:g.godin@hlstherapeutics.com)

---

<https://hlstherapeutics.investorroom.com/2018-03-19-HLS-Therapeutics-to-Host-2017-Fourth-Quarter-and-Year-End-Results-Conference-Call>